The highly anticipated presentation will be delivered by Francisco Silva, Vice President of Research and Development at BioRestorative, on Friday, June 13, at 5:00 p.m. HKT, as part of ISSCR 2025’s ...

"Bill’s appointment comes at a pivotal time as SEED advances its differentiated pipeline into clinical trials and expands global strategic partnerships,” said Dr. Lan Huang, Co-Founder, Chairman, and ...

AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia and other conditions. Esreboxetine, the SS-enantiomer of reboxetine, is more ...

Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial ...

Company to host conference call and webcast today at 8:00 A.M. ET ...

The webinar of the Annual Meeting may be accessed by registering in advance at: https://us06web.zoom.us/webinar/register/WN_NHDxe61oQDi-t84JgMylsg#/registration.

A live stream of the presentation will be available here and on the Investor Relations section of Bio-Path’s website, where it will be archived for approximately 90 days. About Bio-Path Holdings, Inc.

The Nugevia launch adds a new dimension to Jupiter’s value proposition as a dual-path company—advancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming ...

MINNEAPOLIS, June 09, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today announced that it has closed its previously-announced transaction to ...

Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: ...

Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the Company (“the Common Shares”) from time to time in accordance with applicable securities laws, representing ...

Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer’s disease biomarker in both ...